King's College London

Research portal

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment

Research output: Contribution to journal › Letter › peer-review

Standard

Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature : Comment. / Cohen, Hannah; Hunt, Beverley J.; Efthymiou, Maria et al.

In: Current Rheumatology Reports, Vol. 19, No. 8, 50, 08.2017.

Research output: Contribution to journal › Letter › peer-review

Harvard

Cohen, H, Hunt, BJ, Efthymiou, M, Mackie, IJ, Khamashta, M, Isenberg, DA & RAPS Trial Investigators 2017, 'Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment', Current Rheumatology Reports, vol. 19, no. 8, 50. https://doi.org/10.1007/s11926-017-0675-3

APA

Cohen, H., Hunt, B. J., Efthymiou, M., Mackie, I. J., Khamashta, M., Isenberg, D. A., & RAPS Trial Investigators (2017). Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. Current Rheumatology Reports, 19(8), [50]. https://doi.org/10.1007/s11926-017-0675-3

Vancouver

Cohen H, Hunt BJ, Efthymiou M, Mackie IJ, Khamashta M, Isenberg DA et al. Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. Current Rheumatology Reports. 2017 Aug;19(8). 50. https://doi.org/10.1007/s11926-017-0675-3

Author

Cohen, Hannah ; Hunt, Beverley J. ; Efthymiou, Maria et al. / Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature : Comment. In: Current Rheumatology Reports. 2017 ; Vol. 19, No. 8.

Bibtex Download

@article{708d3b32b2204616b501d1dee7d40e28,
title = "Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment",
abstract = "We respond to comments by Dufrost et al. about the RAPS trial, in particular, showing that the trial did achieve its target sample size; pointing out that thrombin potential is not synonymous with overall thrombin generation; confirming that overall, no increased thrombotic risk was evident comparing rivaroxaban with warfarin; and that high-risk patients (28% were triple positive, representative of patients with venous thromboembolism requiring standard-intensity anticoagulation) were included; and clarifying our rationale for using a laboratory surrogate primary outcome measure instead of a clinical one.",
keywords = "Antiphospholipid syndrome, Rivaroxaban, Thrombin generation, Venous thromboembolism, Warfarin",
author = "Hannah Cohen and Hunt, {Beverley J.} and Maria Efthymiou and Mackie, {Ian J.} and Munther Khamashta and Isenberg, {David A.} and {RAPS Trial Investigators}",
year = "2017",
month = aug,
doi = "10.1007/s11926-017-0675-3",
language = "English",
volume = "19",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "8",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature

T2 - Comment

AU - Cohen, Hannah

AU - Hunt, Beverley J.

AU - Efthymiou, Maria

AU - Mackie, Ian J.

AU - Khamashta, Munther

AU - Isenberg, David A.

AU - RAPS Trial Investigators

PY - 2017/8

Y1 - 2017/8

N2 - We respond to comments by Dufrost et al. about the RAPS trial, in particular, showing that the trial did achieve its target sample size; pointing out that thrombin potential is not synonymous with overall thrombin generation; confirming that overall, no increased thrombotic risk was evident comparing rivaroxaban with warfarin; and that high-risk patients (28% were triple positive, representative of patients with venous thromboembolism requiring standard-intensity anticoagulation) were included; and clarifying our rationale for using a laboratory surrogate primary outcome measure instead of a clinical one.

AB - We respond to comments by Dufrost et al. about the RAPS trial, in particular, showing that the trial did achieve its target sample size; pointing out that thrombin potential is not synonymous with overall thrombin generation; confirming that overall, no increased thrombotic risk was evident comparing rivaroxaban with warfarin; and that high-risk patients (28% were triple positive, representative of patients with venous thromboembolism requiring standard-intensity anticoagulation) were included; and clarifying our rationale for using a laboratory surrogate primary outcome measure instead of a clinical one.

KW - Antiphospholipid syndrome

KW - Rivaroxaban

KW - Thrombin generation

KW - Venous thromboembolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=85025095227&partnerID=8YFLogxK

U2 - 10.1007/s11926-017-0675-3

DO - 10.1007/s11926-017-0675-3

M3 - Letter

AN - SCOPUS:85025095227

VL - 19

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 8

M1 - 50

ER -

View graph of relations

By the same authors

With some of the same researchers

From the same journal

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454